Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Amyris, Inc. (“Amyris” or the "Company") (NasdaqGS: AMRS) stock between April 29, 2011 and February 8, 2012.

Click here to learn more about the investigation http://zlk.9nl.com/amyris-amrs/, or call: 877-363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the Class Period, Amyris made materially false and misleading statements concerning the production of Biofene and the Company’s ability to produce Biofene in commercially meaningful volumes.

On November 1, 2011, Amyris disclosed it would not be able to produce Biofene in the quantities previously represented, but that it had identified and learned to address issues that would allow it to raise the volumes. In reaction to this news, shares of Amyris fell more than 20% to close at $15.47 per share. Then on February 9, 2012, Amyris reported a further slowdown in Biofene production and the need to raise funds; as a result of this news, shares of Amyris fell to $6.99 per share.

If you suffered a loss in Amyris you have until July 15, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/amyris-amrs/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010